Neurogene (NGNE) Other Non-Current Assets (2013 - 2026)
Neurogene's (NGNE) quarterly Other Non-Current Assets came in at $1.1 million in Q1 2026, up 20.31% YoY from $896000.0 in Q1 2025, and up 217.99% on a QoQ basis from $339000.0 in Q4 2025.
Analysis
Neurogene (NGNE) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 11 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 20.31% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 20.31% YoY) and the FY2025 annual result came in at $339000.0, down 65.23% from the prior year.
- Other Non-Current Assets grew to $1.1 million in Q1 2026, from $339000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.0 million in Q2 2022 to a low of $300000.0 in Q2 2024.
- A 5-year average of $917375.0 and a median of $842500.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 73.81% — and 2025, when it jumped 164.31%.
- Tracing NGNE's Other Non-Current Assets over 5 years: stood at $1.9 million in 2022, then tumbled by 60.04% to $764000.0 in 2023, then advanced by 27.62% to $975000.0 in 2024, then sank by 65.23% to $339000.0 in 2025, then surged by 217.99% to $1.1 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.1 million (Q1 2026), $339000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | 1.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 896,000.00 |
| Dec 31, 2024 | 975,000.00 |
| Sep 30, 2024 | 789,000.00 |
| Jun 30, 2024 | 794,000.00 |
| Mar 31, 2024 | 743,000.00 |
| Dec 31, 2023 | 764,000.00 |
| Sep 30, 2023 | 524,000.00 |
| Jun 30, 2023 | 529,000.00 |
| Mar 31, 2023 | 905,000.00 |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | 1.95 Mn |
| Dec 31, 2021 | 1.93 Mn |
| Sep 30, 2021 | 1.99 Mn |
| Jun 30, 2021 | 1.93 Mn |